ADAR1 Capital Management »

Arbutus Biopharma shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Arbutus Biopharma (ABUS) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Arbutus Biopharma

Tip: Access up to 7 years of quarterly data

All positions including Arbutus Biopharma held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Arbutus Biopharma by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2024-03-31 $5.4M 2.1M 2.58
2023-12-31 $9.1M 3.6M 2.50

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Roivant Sciences SHS (ROIV)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Protagonist Therapeutics (PTGX)
Cytokinetics Com New (CYTK)
Keros Therapeutics (KROS)
Royalty Pharma Shs Class A (RPRX)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New
Ascendis Pharma A/s Sponsored Adr (ASND)
Arbutus Biopharma (ABUS)
Avrobio Ord (AVRO)
Beigene Sponsored Adr (BGNE)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)

View all positions for ADAR1 Capital Management

Top funds holding Arbutus Biopharma

Morgan Stanley
Whitefort Capital Management
BlackRock
BlackRock
Two Seas Capital
Vanguard Group
Geode Capital Management
State Street Corporation
BlackBarn Capital Partners
Rubric Capital Management
Squarepoint Ops
Advisor Group Holdings
Northern Trust
Charles Schwab Investment Management
Hudson Bay Capital Management

View all funds holding Arbutus Biopharma